Plenary Session 10











Attenzione: apre in una nuova finestra.

10 Tuesday, September 4, 9:40 – 11:25 am

Esophageal cancer
Chairs: P.M. Schneider (Zurich) – J.M. Collard (Brussels)
Discussant: S. Law (Hong Kong)  

  • What testing should be made for targeted therapy in esophageal cancers? D.H. Ilson (New York)
  • Does the level of the intra-thoracic esophago-gastrostomy matter with respect to lymphadenectomy and outcome? M.S. Allen (Rochester, MN)
  • Is minimally-invasive esophagectomy as good as open surgery? J. Räsänen (Helsinki)
  • Is there still a role for surgical resection of cervical esophageal squamous cell cancer? S. Law (Hong Kong)
  • Are pure surgical arms still justified in future randomized trials evaluating multimodality treatment regimens? M. Krasna (Neptune)
  • Does neo-adjuvant treatment in past randomized trials compensate for low quality surgery or is it truly beneficial? P.M. Schneider (Zurich)
  • Should early FDG-PET response monitoring be performed in neo-adjuvant treatment strategies? D.H. Ilson (New York)
  • What is the current impact of molecular response evaluation in neo-adjuvant treatment strategies? D. Kandioler (Vienna)
  • What is the short and long term toxicity of definitive chemo-radiation and should we follow our patients? B.P. Wijnhoven (Rotterdam)
  • What type of anastomosis should be performed after subtotal esophagectomy? J.M.  Collard (Brussels)
  • Should para-aortic lymph node dissection be performed in E-G junction tumors? M. Schiesser (Zurich)
  • What is the best strategy for T2 esophageal cancer? M. Krasna (Neptune)
  • Do m3- sm1 cancers need radical esophagectomy after endoscopic resection for staging? E.D. Pirchi (Buenos Aires)
  • Does EUS provide additional useful information to PET-CT regarding lymph node metastases? N.D. Maynard (Oxford)